New Study Finds Big Pharma Company Merck Misled Participants in HPV Vaccine Trial

Angeline Tan : Jul 23, 2024
LifeSiteNews.com

...The advertising material for the trial and the informed consent forms stated that the placebo was saline or an inactive substance, when, in fact, it contained Merck's proprietary highly reactogenic aluminum adjuvant which does not appear to have been properly evaluated for safety. Consequently, "several trial participants experienced chronic disabling symptoms, including some randomized to the adjuvant ‘placebo' group," the study added.

[LifeSiteNews.com] A recent study published in the International Journal of Risk & Safety in Medicine in May this year found that pharmaceutical company Merck & Co. was involved in scientific fraud when it misled participants in its HPV vaccine trial.  (Image: Pixabay) 

Merck designed a clinical trial that stated: "One half of the participants will receive the active vaccine, while the other half will get the placebo vaccine." (A placebo vaccine refers to a vaccine without active substance.) It didn't tell the whole story, however.

The medical study elaborated: 

It was found that the vaccine manufacturer Merck made several inaccurate statements to trial participants that compromised their right to informed consent. First, even though the study protocol listed safety testing as one of the study's primary objectives, the recruitment brochure emphasized that FUTURE II was not a safety study, and that the vaccine had already been proven safe. Second, the advertising material for the trial and the informed consent forms stated that the placebo was saline or an inactive substance, when, in fact, it contained Merck's proprietary highly reactogenic aluminum adjuvant which does not appear to have been properly evaluated for safety.

Consequently, "several trial participants experienced chronic disabling symptoms, including some randomized to the adjuvant 'placebo' group," the study added.

The same report stated: 

The informed consent forms for Merck's Gardasil vaccine trials appear to be seriously misleading, as a highly reactogenic adjuvant with a questionable safety record was described as an inactive placebo. Thus, in our opinion, there was a violation of the scientific principle in the failure to use a true placebo, and of ethics in the failure to disclose the true composition of the 'placebo'.

Current animal and human research indicate that aluminum adjuvants may be associated with persisting and disabling systemic symptoms and neurological impairments. It is therefore unclear why the drug regulatory agencies continue to endorse the use of aluminum adjuvant 'placebos' in vaccine clinical trials. This practice hinders proper assessment of vaccine harms and appears to violate medical ethics guidelines as it exposes research subjects to potential risks only without any benefit... Subscribe for free to Breaking Christian News here

Continue reading Here.